Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era.
Del Río-Garma J, Bobillo S, de la Rubia J, Pascual C, García-Candel F, García-Gala JM, Gonzalez R, Abril L, Vidan J, Gomez MJ, Peña F, Arbona C, Martín-Sanchez J, Moreno G, Romón I, Viejo A, Oliva A, Linares M, Salinas R, Pérez S, Garcia-Erce JA, Pereira A; “Registro Español de la Púrpura Trombocitopénica Trombótica (REPTT)”, and the “Grupo Español de Aféresis (GEA)”. Del Río-Garma J, et al. Ann Hematol. 2022 Jan;101(1):59-67. doi: 10.1007/s00277-021-04685-8. Epub 2021 Oct 12. Ann Hematol. 2022. PMID: 34642787
Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura.
Pascual-Izquierdo C, Del Rio-Garma J, de la Rubia J, Viejo A, Mingot E, Cid J, Solanich X, Fernández-Sojo J, Martín-Sánchez J, Hernández L, García-Gala JM, Alonso N, González V, Oliva A, Gómez-Seguí I, Goterris R, Guerra L, García-Candel F, Fernández-Docampo M, Antelo ML, Salgado-Barreira Á, Salinas R; Spanish Apheresis Group (GEA) and Spanish Thrombotic Thrombocytopenic Purpura Registry (REPTT). Pascual-Izquierdo C, et al. J Clin Apher. 2021 Aug;36(4):563-573. doi: 10.1002/jca.21894. Epub 2021 Mar 29. J Clin Apher. 2021. PMID: 33780553
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial.
Puig N, Corchete-Sánchez LA, Pérez-Morán JJ, Dávila J, Paíno T, de la Rubia J, Oriol A, Martín-Sánchez J, de Arriba F, Bladé J, Blanchard MJ, González-Calle V, García-Sanz R, Paiva B, Lahuerta JJ, San-Miguel JF, Mateos MV, Ocio EM. Puig N, et al. Cancers (Basel). 2020 Dec 3;12(12):3615. doi: 10.3390/cancers12123615. Cancers (Basel). 2020. PMID: 33287189 Free PMC article.
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
Ocio EM, Motlló C, Rodríguez-Otero P, Martínez-López J, Cejalvo MJ, Martín-Sánchez J, Bladé J, García-Malo MD, Dourdil MV, García-Mateo A, de Arriba F, García-Sanz R, de la Rubia J, Oriol A, Lahuerta JJ, San-Miguel JF, Mateos MV. Ocio EM, et al. Br J Haematol. 2021 Feb;192(3):522-530. doi: 10.1111/bjh.16788. Epub 2020 Jun 5. Br J Haematol. 2021. PMID: 32501528 Free article. Clinical Trial.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Goicoechea I, Puig N, Cedena MT, Burgos L, Cordón L, Vidriales MB, Flores-Montero J, Gutierrez NC, Calasanz MJ, Ramos MM, Lara-Astiaso D, Vilas-Zornoza A, Alignani D, Rodriguez I, Sarvide S, Alameda D, Garcés JJ, Rodriguez S, Fresquet V, Celay J, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Rios R, Martin-Sanchez J, Martinez-Martinez R, Sarra J, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Martinez-Climent JA, Orfao A, Rosiñol L, Mateos MV, Lahuerta JJ, Blade J, San Miguel J, Paiva B. Goicoechea I, et al. Blood. 2021 Jan 7;137(1):49-60. doi: 10.1182/blood.2020006731. Blood. 2021. PMID: 32693406 Free article. Clinical Trial.
Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.
Colado E, Paíno T, Maiso P, Ocio EM, Chen X, Alvarez-Fernández S, Gutiérrez NC, Martín-Sánchez J, Flores-Montero J, San Segundo L, Garayoa M, Fernández-Lázaro D, Vidriales MB, Galmarini CM, Avilés P, Cuevas C, Pandiella A, San-Miguel JF. Colado E, et al. Haematologica. 2011 May;96(5):687-95. doi: 10.3324/haematol.2010.036400. Epub 2011 Feb 17. Haematologica. 2011. PMID: 21330323 Free PMC article.
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, García-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF; Spanish Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Groups. Paiva B, et al. Blood. 2016 Apr 14;127(15):1896-906. doi: 10.1182/blood-2015-08-665679. Epub 2016 Jan 11. Blood. 2016. PMID: 26755711 Free article. Clinical Trial.
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Mateos MV, Prosper F, Martin Sánchez J, Ocio EM, Oriol A, Motlló C, Michot JM, Jarque I, Iglesias R, Solé M, Martínez S, Kahatt C, Fudio S, Corral G, Zeaiter A, Montilla L, Ribrag V. Mateos MV, et al. Cancer Med. 2023 Feb;12(4):3999-4009. doi: 10.1002/cam4.5250. Epub 2022 Sep 20. Cancer Med. 2023. PMID: 36127823 Free PMC article. Clinical Trial.
239 results